On May 7, 2021, the World Health Organization announced that the new crown inactivated vaccine developed by China National Pharmaceutical Group Beijing Institute of Biological Products has officially passed the WHO emergency use certification.

WHO Director-General Tedros Adhanom Ghebreyesus said that the WHO issued emergency use certification for China's Sinopharm's new crown vaccine that afternoon, making it the sixth new crown vaccine to obtain WHO's safety, effectiveness and quality verification. This expands the WHO-led "New Coronary Pneumonia Vaccine Implementation Plan" (COVAX) combined vaccine library list, and helps countries speed up the regulatory approval of the new coronavirus vaccine.

Marianjeira Simao, WHO's Assistant Director-General in charge of obtaining medicines and health products, said that including China's Sinopharm's new crown vaccine in the WHO emergency use list "helps countries seeking to protect health workers and high-risk groups accelerate access. New crown vaccine".

China's new crown vaccine use certification

The easy storage of Sinopharm's new crown vaccine makes it very suitable for resource-poor environments. It is also the first vaccine to carry a vaccine vial monitor. The small label on the vaccine vial will change color due to the heating of the vaccine, so that health workers can judge whether the vaccine is safe and available. According to the opinion of the WHO immunization strategy consulting expert group, the WHO recommends that the Chinese National Medicine Covid-19 vaccine be used for adults 18 years and older, with two injections with an interval of 3 to 4 weeks. In all age groups participating in the trial, the vaccine's effective rate for symptomatic patients and hospitalized patients was estimated to be 79%. In addition, the World Health Organization does not recommend setting an upper age limit for China's Sinopharm's new crown vaccine, because evaluation data show that the vaccine may also have a protective effect on the elderly.

Prior to this, the WHO has issued emergency use certifications to five new crown vaccines, which are the new crown vaccine jointly developed by Pfizer Pharmaceuticals Co., Ltd. of the United States and the German Biotech Company, and two versions jointly developed by AstraZeneca Pharmaceuticals of the United Kingdom and the University of Oxford. AstraZeneca vaccine, the new crown vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and the new crown vaccine developed by Modena of the United States. Editor/Tian Zengpeng